繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
牛牛AI助理已提取核心訊息
BeiGene announced the appointment of Shalini Sharp to its Board of Directors and Audit Committee, effective September 27, 2024. The Board size increased from 11 to 12 members. Sharp, 49, brings extensive experience in the pharmaceutical and financial sectors, currently serving on the boards of Neurocrine Biosciences and Organon & Co.Sharp will receive equity awards valued at $400,000 (pro-rated in the first year), annual cash compensation of $65,000 for board service and $17,500 for Audit Committee membership. She will serve as a Class III director until the 2025 annual meeting. BeiGene CEO John V. Oyler highlighted Sharp's global pharmaceutical leadership experience as valuable for the company's growth phase.Previously, Sharp held CFO positions at Ultragenyx Pharmaceuticals and Agenus Inc. She also served on boards of several biopharmaceutical companies. Sharp's appointment is expected to contribute to BeiGene's strategic growth and financial expertise as it expands globally and advances its cancer therapy pipeline.
BeiGene announced the appointment of Shalini Sharp to its Board of Directors and Audit Committee, effective September 27, 2024. The Board size increased from 11 to 12 members. Sharp, 49, brings extensive experience in the pharmaceutical and financial sectors, currently serving on the boards of Neurocrine Biosciences and Organon & Co.Sharp will receive equity awards valued at $400,000 (pro-rated in the first year), annual cash compensation of $65,000 for board service and $17,500 for Audit Committee membership. She will serve as a Class III director until the 2025 annual meeting. BeiGene CEO John V. Oyler highlighted Sharp's global pharmaceutical leadership experience as valuable for the company's growth phase.Previously, Sharp held CFO positions at Ultragenyx Pharmaceuticals and Agenus Inc. She also served on boards of several biopharmaceutical companies. Sharp's appointment is expected to contribute to BeiGene's strategic growth and financial expertise as it expands globally and advances its cancer therapy pipeline.
百濟神州宣佈任命Shalini Sharp爲董事會和審計委員會成員，任命自2024年9月27日起生效。董事會規模從11名成員增加到12名成員。49歲的Sharp在藥品和金融領域擁有廣泛的經驗，目前在神經分泌生物科學和Organon & Co.的董事會中任職。Sharp將獲得價值40萬美元的股權獎勵（首年按比例分配），年度現金報酬爲6.5萬美元作爲董事服務費，審計委員會成員費爲1.75萬美元。她將擔任三類董事，直到2025年年度會議。百濟神州CEO John V. Oyler強調Sharp在全球藥品領導經驗對公司增長階段的重要性。此前，Sharp曾擔任Ultragenyx Pharmaceuticals和Agenus Inc.的CFO。她還曾在多家生物製藥公司的董事會任職。Sharp的任命預計將有助於百濟神州的戰略增長和金融專業知識，隨着公司在全球擴展並推進其癌症治療管線。
百濟神州宣佈任命Shalini Sharp爲董事會和審計委員會成員，任命自2024年9月27日起生效。董事會規模從11名成員增加到12名成員。49歲的Sharp在藥品和金融領域擁有廣泛的經驗，目前在神經分泌生物科學和Organon & Co.的董事會中任職。Sharp將獲得價值40萬美元的股權獎勵（首年按比例分配），年度現金報酬爲6.5萬美元作爲董事服務費，審計委員會成員費爲1.75萬美元。她將擔任三類董事，直到2025年年度會議。百濟神州CEO John V. Oyler強調Sharp在全球藥品領導經驗對公司增長階段的重要性。此前，Sharp曾擔任Ultragenyx Pharmaceuticals和Agenus Inc.的CFO。她還曾在多家生物製藥公司的董事會任職。Sharp的任命預計將有助於百濟神州的戰略增長和金融專業知識，隨着公司在全球擴展並推進其癌症治療管線。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了